Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results

Coya Therapeutics (NASDAQ:COYA) released its quarterly earnings data on Tuesday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07, FiscalAI reports. The firm had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.15 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.

Coya Therapeutics Price Performance

NASDAQ:COYA traded up $0.05 during mid-day trading on Tuesday, reaching $4.23. The company’s stock had a trading volume of 366,751 shares, compared to its average volume of 184,783. The company’s fifty day simple moving average is $4.39 and its two-hundred day simple moving average is $5.09. Coya Therapeutics has a twelve month low of $3.71 and a twelve month high of $7.75. The stock has a market cap of $99.24 million, a P/E ratio of -3.33 and a beta of 0.55.

Institutional Trading of Coya Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new stake in Coya Therapeutics in the 4th quarter worth about $192,000. Occudo Quantitative Strategies LP acquired a new stake in Coya Therapeutics in the 4th quarter worth about $66,000. Millennium Management LLC acquired a new stake in Coya Therapeutics in the 4th quarter worth about $121,000. 683 Capital Management LLC acquired a new stake in Coya Therapeutics in the 4th quarter worth about $465,000. Finally, Cetera Investment Advisers purchased a new position in shares of Coya Therapeutics in the 4th quarter worth about $128,000. 39.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a report on Monday, April 20th. Chardan Capital reissued a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Monday, March 16th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, March 23rd. Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Friday, April 10th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.